The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo, Mitsubishi UFJ Capital Establish New Fund to Support Ventures in Japan
September 19, 2013
- Eslicarbazepine Monotherapy Meets Primary Endpoint in PIII Trials: DSP
September 19, 2013
- GSK to Return All Rights to EPO Biosimilar to JCR Pharmaceuticals
September 19, 2013
- Kyowa Kirin Aims for 10% Share in a Highly Competitive Market for Diabetes Treatments, but Onglyza’s Chances of Success Remain in Doubt
September 19, 2013
- Demand Growing for Transdermal Patches in Graying Japan, Drug Makers Gear Up for Development
September 18, 2013
- Otsuka’s Samsca Wins Add’l Indication for Fluid Retention in Liver Cirrhosis Patients; World’s 1st Such Approval
September 18, 2013
- Takeda Grants Arbor Exclusive Rights for Edarbi Family of Products in US
September 17, 2013
- Xalkori Significantly Extends PFS in Japanese Patients: Pfizer
September 17, 2013
- Chugai Launches Breast Cancer Drug Parjeta
September 13, 2013
- Eisai Launches Halaven in Russia, First Product to Be Marketed by Company
September 13, 2013
- Hisamitsu Initiates PII Study of Transdermal Ropinirole for RLS Treatment in Japan
September 13, 2013
- Generic Drug Market Shows Steady Growth in 1st Quarter; Eisai, Meiji Seika Pharma Report Sharpest Growth in Sales
September 13, 2013
- Taiho’s TS-1 Failed to Significantly Improve Survival of Patients in Second-Line Treatment
September 12, 2013
- Nippon Kayaku’s Filing of Remicade Biosimilar Heralds Age of Major Biologic Follow-Ons
September 12, 2013
- Ono to Set Up New Strategic Division for Nivolumab
September 12, 2013
- Merck Serono Launches Human Growth Hormone Preparation Saizen 12 mg Subcutaneous Injection
September 12, 2013
- Nichi-Iko, BioLab Tie Up on Generic Business in Thailand
September 11, 2013
- MTPC Subsidiary in Indonesia to Construct New Production Facility
September 10, 2013
- Kyowa Kirin to Establish New Research Center in Singapore, Conduct Joint Research with Local Research Institutes
September 10, 2013
- InCROM Subsidiary in Shanghai Set to Become Subsidiary of Chinese Pharma Giant, Aims for Business Expansion
September 10, 2013
ページ
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…